

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Attorney Docket No.: DEX0478US.NP
Inventors: Wolfert et al.
Serial No.: Not Yet Assigned
Filing Date: Herewith
Examiner: Not Yet Assigned
Customer No.: 32800
Group Art Unit: Not Yet Assigned
Confirmation No.: Not Yet Assigned
Title: New Uses of Lp-PLA2 in Combination to Assess Coronary Risk

"Express Mail" Label No. EV680435036US

Date of Deposit October 3, 2005

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents Post Office Box 1450, Box PCT, Alexandria, VA 22313-1450

By


Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is attached hereto; or
- () Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.


Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

(XX) Copies of the PCT Search Report from PCT Application No. PCT/US2004/010039, which corresponds to this U.S. Patent Application are included.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,


Kathleen A. Tyrrell
Registration No. 38,350

Date: October 3, 2005

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Docket No. DEX0478US.NP	Serial No. 10/552084 Not Yet Assigned
		Applicant Wolfert et al.	
		Filing Date Herewith	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Packard et al., "Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease", The New England Journal of Medicine 2000 343(16):1148-1155	
	AB	Heart Protection Study Collaborative Group, "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals:a randomised placebo-controlled trial", The Lancet 2002 360(9326):7-22	
EXAMINER		DATE CONSIDERED	